FAB4-guided P4 immune therapy for prostate cancer

The project in a nutshell

Testing whether a protein drug called FAB4 can make the body's own immune system attack prostate cancer cells.

Why we funded it

If successful, FAB4-guided immunotherapy could provide a new treatment for men affected by advanced and otherwise untreatable prostate cancer, helping to improve survival and quality of life.

Grant information

Institution - King's College London
Researcher - Dr Sophie Papa
Grant award - £50,000
Duration - 2013-2014
Reference - PA12-06 Papa